PACIFIC BIOSCIENCES OF CALIFORNIA (PACB)
Health Care · Genomic sequencing instruments and solutions · NASDAQ
PacBio develops HiFi long-read DNA sequencing systems that deliver complete, accurate genomic insights for clinical and research applications.
What PACIFIC BIOSCIENCES OF CALIFORNIA does
Pacific Biosciences designs, develops, and manufactures advanced sequencing solutions based on HiFi long-read sequencing technology. The company serves academic research institutions, clinical laboratories, pharmaceutical companies, and agricultural organizations with products addressing human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and emerging genomic applications. PacBio's systems are designed to provide the most complete and accurate view of genomes, transcriptomes, and epigenomes to resolve genetically complex problems.
Themes: ["Long-read genomic sequencing","Clinical genomics / whole-genome sequencing","Rare disease diagnosis","Genomics research tools","Precision medicine / genetic testing","Agricultural genomics","Oncology genomics","AI-assisted genomic data interpretation"]
Fundamentals
- Price$1.61 as of 2026-07-09 close
- Market cap$466M as of 2026-07-10
- 1-year return+8.8% as of 2026-07-09 close
- Net margin-80.3% as of 2026-07-10
- Gross margin+40.3% as of 2026-07-10
- ROE-488.4% as of 2026-07-10
- Debt / equity272.23 as of 2026-07-10
- Revenue growth (YoY)+5.0% as of 2026-07-10
- Revenue CAGR (3y)-6.9% SEC XBRL
- Beta2.34 as of 2026-07-10
Key risks (from latest filing)
["Unprofitable operations with -80.34% net margin; company is burning cash and dependent on capital access to fund R&D and growth initiatives.","Competitive pressure from established players like Illumina with significantly greater scale, resources, and market share in DNA sequencing.","Clinical adoption risk: success hinges on broad uptake of HiFi sequencing in laboratory-developed tests and clinical settings, which remains unproven at scale."]
Competitors & peers
- Illumina (ILMN)
- Oxford Nanopore Technologies
- 10x Genomics
- Element Biosciences
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.